FDA Drug recall D-0707-2022
Norepinephrine Bitartrate Injection 16 mg per 250 mL added to 0.9% Sodium Chloride, 16 mg, 250 mL excel bag, Rx only, Athenex Pharma Soluti…
- FDA Drug
- Class II
- terminated
- Published 2022-03-30
On 2022-03-30 the FDA classified a Class II recall of Norepinephrine Bitartrate Injection 16 mg per 250 mL added to 0.9% Sodium Chloride, 16 mg, 250 mL excel bag, Rx only, Athenex Pharma Soluti… by Athenex Pharma Solutions, citing defective container.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0707-2022 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2022-03-14 |
| Published | 2022-03-30 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Athenex Pharma Solutions |
| Distribution | US |
Product
Norepinephrine Bitartrate Injection 16 mg per 250 mL added to 0.9% Sodium Chloride, 16 mg, 250 mL excel bag, Rx only, Athenex Pharma Solutions, LLC, Clarence, NY, 14031, NDC 76154-476-15
Reason
Defective container
Identifiers
| code_info | Lot #: F2101634, Exp 3/30/22; F2101665, F2101666, Exp 4/02/22; F2101788, F2101789, Exp 4/26/22; F2101811, F2101812, F2101815, Exp 4/29/22 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0707-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.